Surgery Partners (NASDAQ:SGRY) Issues Earnings Results

Surgery Partners (NASDAQ:SGRY - Get Free Report) issued its earnings results on Monday. The company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.01, Zacks reports. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. Surgery Partners updated its FY 2025 guidance to EPS.

Surgery Partners Price Performance

SGRY stock opened at $24.08 on Monday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.66 and a current ratio of 1.80. The stock's 50 day moving average price is $23.04 and its 200 day moving average price is $26.45. The firm has a market cap of $3.06 billion, a P/E ratio of -50.17, a PEG ratio of 19.21 and a beta of 2.60. Surgery Partners has a 1 year low of $19.50 and a 1 year high of $33.97.

Insider Activity

In other Surgery Partners news, CEO Jason Eric Evans sold 26,520 shares of the company's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $25.65, for a total value of $680,238.00. Following the transaction, the chief executive officer now directly owns 560,698 shares of the company's stock, valued at $14,381,903.70. This represents a 4.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Harrison R. Bane sold 56,315 shares of Surgery Partners stock in a transaction on Friday, February 7th. The stock was sold at an average price of $25.64, for a total transaction of $1,443,916.60. Following the completion of the transaction, the insider now directly owns 107,037 shares of the company's stock, valued at approximately $2,744,428.68. This represents a 34.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 96,733 shares of company stock valued at $2,480,106 over the last 90 days. Insiders own 2.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on SGRY shares. Macquarie reiterated an "outperform" rating and set a $34.00 price target on shares of Surgery Partners in a research note on Tuesday, November 19th. Royal Bank of Canada cut their target price on shares of Surgery Partners from $49.00 to $35.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 20th. JPMorgan Chase & Co. decreased their price target on shares of Surgery Partners from $38.00 to $28.00 and set a "neutral" rating for the company in a research report on Tuesday, December 3rd. Finally, Bank of America initiated coverage on Surgery Partners in a research report on Monday, December 16th. They set a "buy" rating and a $30.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $36.56.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.